Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma

Yonathan Lissanu Deribe, Yanxia Shi, Kunal Rai, Luigi Nezi, Samir B. Amin, Chia-Chin Wu, Kadir C. Akdemir, Mozhdeh Mahdavi, Qian Peng, Qing Edward Chang, Kirsti Hornigold, Stefan T. Arold, Heidi C. E. Welch, Levi A. Garraway, Lynda Chin

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Abstract

PREX2 (phosphatidylinositol-3,4,5-triphosphate-dependent Rac-exchange factor 2) is a PTEN (phosphatase and tensin homolog deleted on chromosome 10) binding protein that is significantly mutated in cutaneous melanoma and pancreatic ductal adenocarcinoma. Here, genetic and biochemical analyses were conducted to elucidate the nature and mechanistic basis of PREX2 mutation in melanoma development. By generating an inducible transgenic mouse model we showed an oncogenic role for a truncating PREX2 mutation (PREX2E824*) in vivo in the context of mutant NRAS. Using integrative cross-species gene expression analysis, we identified deregulated cell cycle and cytoskeleton organization as significantly perturbed biological pathways in PREX2 mutant tumors. Mechanistically, truncation of PREX2 activated its Rac1 guanine nucleotide exchange factor activity, abolished binding to PTEN and activated the PI3K (phosphatidyl inositol 3 kinase)/Akt signaling pathway. We further showed that PREX2 truncating mutations or PTEN deletion induces down-regulation of the tumor suppressor and cell cycle regulator CDKN1C (also known as p57KIP2). This down-regulation occurs, at least partially, through DNA hypomethylation of a differentially methylated region in chromosome 11 that is a known regulatory region for expression of the CDKN1C gene. Together, these findings identify PREX2 as a mediator of NRAS-mutant melanoma development that acts through the PI3K/PTEN/Akt pathway to regulate gene expression of a cell cycle regulator.
Original languageEnglish (US)
Pages (from-to)E1296-E1305
Number of pages1
JournalProceedings of the National Academy of Sciences
Volume113
Issue number9
DOIs
StatePublished - Feb 16 2016

Bibliographical note

KAUST Repository Item: Exported on 2020-10-01
Acknowledgements: We thank Timothy Heffernan and Trang Tieu of the Institute for Applied Cancer Science for help with various plasmids, Jim Horner and Erin Paul of the MD Anderson GEM facility for pronuclear injection of PREX2 transgene, and Chang-Gong Liu of MD Anderson Sequencing and Non-coding RNA Core Facility for microarray profiling and Denise Spring for critical reading of the manuscript. L.C is a recipient of the Cancer Prevention and Research Institute of Texas (CPRIT) Established Investigator Recruitment Award. S.T.A. was supported by the King Abdullah University of Science and Technology.

Fingerprint

Dive into the research topics of 'Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma'. Together they form a unique fingerprint.

Cite this